Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 42 for “"Anti-VEGF"”.
-
A Kinetic Study of Anti-VEGF-A Polyclonal Antibodies and Anti-VEGF-A ssDNA Aptamers
… reagent that could possibly augment or replace antibodies research and diagnosis methods are aptamers. Aptamers are ssDNA, RNA or polypeptide constructs that function like active antibodies. Antibodies and aptamers both specifically bind to selected target molecules, and as such they enable the …
-
Renal and kardiovaskulär adverse events after anti-VEGF-treatment
… Thema renaler und kardialer Nebenwirkungen nach anti-VEGF-Behandlung. Case reports von Patienten mit refraktären Schilddrüsenkarzinomen und möglicher Nebenwirkungen nach TKI-Behandlung.
-
Role of Macrophages In Adaptive Resistance to Anti-Vegf Therapy
… implementation of therapies targeting the VEGF pathway in cancer has been limited by acquired resistance; yet, the mechanisms by which this occurs is unclear. We investigated the role of macrophages in the development of acquired resistance to anti-VEGF antibody (AVA) therapy.</p> …
-
Comparing Anti-VEGF Antibodies and Aptamers on Paper Microfluidic-Based Platforms
… conjugate reagents. In the detection region both antibodies and aptamers were evaluated.</p> <p>The fiberglass pad where conjugate reagents would be contained, were initially saturated in dye. As sample was inputted into the three-dimensional chip, the fluid path could be visualized. Without the …
-
Anti-VEGF Therapy Modulates Immune Cell Infiltration and Function in Multiple Breast Cancer Models
… target for tumor therapy. Many of the current anti-angiogenic therapies target vascular endothelial growth factor-A (VEGF). VEGF binds to and activates two primary VEGF receptors, VEGFR1 and VEGFR2. VEGFR2 is the primary angiogenic receptor, while the function of VEGFR1 is less defined. It is …
-
Drug Loaded Multifunctional Microparticles for Anti-VEGF Therapy of Exudative Age-related Macular Degeneration
… to AMD. The current intravitreal injection of anti-VEGF (vascular endothelial growth factor) therapies using Avastin or Lucentis has several unmet clinical needs, such as to minimize the frequency of injection, to decrease the systemic side effects, and to evaluate the effect of therapies. We …
-
Biomarcadores sanguíneos predictivos de respuesta al tratamiento anti-VEGF en degeneración macular asociada a la edad
… enfermedad. La inyección intravítrea de agentes anti-VEGF es actualmente la terapia de primera línea para la neovascularización en pacientes con DMAE neovascular. Sin embargo, un gran número de pacientes no muestran una respuesta satisfactoria a este tratamiento. Los modelos de respuesta al …
-
Role of The Ang-Tie2 Pathway In The Invasive Recurrence of Gbm Following Anti-Vegf Therapy
… of bevacizumab, a humanized monoclonal anti-VEGF antibody, for the treatment of gliomas led to its accelerated approval for the treatment of patients with recurrent glioma. However, despite strong anti-tumor effects, upon treatment with bevacizumab, patients will invariably recur with a …
-
Effects of combination therapies on age-related macular degeneration
… The treatments explored in this paper are: anti-vascular endothelial growth factor (VEGF) drugs, photodynamic therapy (PDT) and steroids. All three require invasive eye procedures that carry their own risks. The possibility of more effective treatments by combining these therapies is being …
-
Genotypes of SNPs of Key Genes Regulate Susceptibility and Drug Sensitivity to Neovascular AMD
… burden. Current optimal treatments hinge on anti-vascular endothelial growth factor (anti-VEGF) therapies, though their efficacy varies across different drugs and individuals, highlighting the importance of precise drug selection in clinical outcomes. Research suggests that factors such as …
-
Anti-vascular endothelial growth factor in ophthalmology
… acuity. Based on an intrinsic understanding of VEGF biology and its critical role in ocular pathogenesis, various anti-VEGF strategies tailored specifically to ophthalmologic illnesses were conceived. Pegaptanib, bevacizumab, ranibizumab, aflibercept, and the more recently authorized …
-
The Immunosuppressive Function of VEGF Signaling in the Tumor Microenvironment
… induced by vascular endothelial growth factor-A (VEGF). As a result, anti-VEGF therapy is commonly employed for cancer treatment. However, anti-VEGF therapy generally provides modest efficacy in cancer patients and therapy-induced hypoxia results in a less differentiated mesenchymal-like tumor …
-
Mechanistic and therapeutic evaluation of a novel antiantiogenic small molecule
… mediator, vascular endothelial growth factor (VEGF). However, repeated injections of anti-VEGF drugs can cause ocular and systemic side effects, and about 30% of wet AMD patients are non-responsive. There is thus an unmet need to develop VEGF-independent antiangiogenic molecules to complement …
-
Development of preformed photo-crosslinked intravitreal implants for protein delivery to the posterior segment of the eye
… is the use of sustained-release implants to give anti-VEGF agents to the patient. <br/><br/>From investigations carried out in this thesis, PEGDA-based photo-crosslinked intravitreal implants have shown long-term delivery of protein over several months while retaining high protein activity. The …
-
Efecto del tratamiento anti-veg sobre los factores de riesgo cardiovascular y biomarcadores de de estrés oxidativo en pacientes con degeneración macular exudativa asociada a la edad
… edad (DMAE) y analizar el efecto de la terapia anti-VEGF (Ranibizumab y Pegaptanib) sobre biomarcadores de estrés oxidativo y factores de RCV. MATERIAL Y MÉTODOS La muestra poblacional está constituida por 163 individuos con DMAE y 170 individuos sanos, a los cuales se determino el RCV. A …
-
Biodegradable in situ forming photocrosslinked implants for sustained protein delivery to the posterior segment of the eye
… is further increased due to the fact that the anti-VEGF agents, used to treat two of the most pertinent sight-threatening conditions - age-related macular degeneration and diabetic retinopathy - are proteins. <br/><br/>This thesis shows the capacity of in situ forming implants, formed from gels …
-
Anatomical and functional correlates in ischaemic retinal vein occlusion
… latter group of patients. In fact, intravitreal anti-VEGF, in particular, proved to be as beneficial in ischaemic forms of RVO as in non-ischaemic forms. However, due to the low baseline vision classically found in the ischaemic form, final vision remains lower than in non-iRVO despite …
-
Uncovering Molecular Targets to Overcome Immunosuppression In Non-Small Cell Lung Cancer With Acquired Tki Resistance
… tyrosine kinase inhibitors (TKIs) or monoclonal antibodies targeting vascular endothelial growth factor (VEGF/R), can effectively inhibit upregulated signaling pathways driving tumorigenesis in NSCLC and many other cancers. Unfortunately, however, resistance to such targeted therapies inevitably …
-
Mechanisms of artralgia in targeted therapies for cancer
… plazmatického séra pacientů léčených terapií anti-vaskulárním endoteliálním růstovým faktorem (anti-VEGF). I když se zdá, že IL-6 je klíčovým faktorem způsobujícím artralgii, byly popsány i další možné mechanismy. Tento článek poskytuje přehled známých informací o vztahu cytokinů a bolesti …
-
Isolation of Therapeutic Antibodies Against Microseminoprotien to Potentially Overcome Resistance to Anti-Angiogenic Therapy
… tumors. To combat the formation of tumors, an anti-VEGF drug, bevacizumab, is used to starve tumors of blood that provide essential nutrients. While platinum-taxane doublet therapy in addition to cytoreductive surgery has been the gold standard treatment for patients with ovarian cancer, …
Page 1 of 3